Dekundy, A., Lundblad, M., Danysz, W. and Cenci, M.A. (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behavioural Brain Research, 179, 76-89. doi:10.1016/j.bbr.2007.01.013

has been cited by the following article:

• TITLE: The effects of L-Dopa and N-(alpha-linolenoyl) tyrosine on 6-OH-DA lesions on dopamine level and activity, dyskinesia and homocysteinemia in rats

  AUTHORS: Shlomo Yehuda, Sharon Rabinovitz-Shenkar

  KEYWORDS: Parkinson; Dopamine; Tolerance; Dyskinesia; Homocysteine; Rotational Behavior

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.2 No.1, February 18, 2013

  ABSTRACT: The three major issues in L-DOPA therapy for Parkinson are: 1) rapid tolerance; 2) induced dyskinesia; 3) hyperhomocysteinemia. The newly synthesized molecule, which is an amide bond molecule composed of L-tyrosine and alphalinolenic acid, i.e., N-(alpha-linolenoyl) tyrosine (NLT), represents a new class of molecules that combines essential amino acids with essential fatty acids. This study demonstrates that acute administration of NLT results in prolonged increase of the brain dopamine level, and that this molecule is able to overcome the three major problems associated with Parkinson’s L-DOPA therapy: it is able to elevate brain dopamine levels and increase activity, without inducing tolerance, dyskinesia or hyperhomocysteinemia.